Melanóma: vizsgálatok itt: Egyesült Királyság

In Egyesült Királyság 34 Also abroad 578

34 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

3. fázisTaking people
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Where
Cambridge, Glasgow, London, Manchester, Oxford, Southampton
Életkor
18 év and over
People
450 worldwide
Run by
Immatics US, Inc.
See details and how to joinNCT06743126 · EU 2024-517062-42-00
1. fázisTaking people
A Study of MGC026 in Participants With Advanced Solid Tumors
Where
Oxford, Sutton
Életkor
18 év and over
People
394 worldwide
Run by
MacroGenics
See details and how to joinNCT06242470
2. fázisTaking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Cambridge, Coventry, London, Nottingham
Életkor
18 év and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
No phaseTaking people
Development and Multi-Centre Validation of a Novel Non-Invasive Melanoma Molecular Diagnostic Test
Where
London
Életkor
18 év and over
People
2000 worldwide
Run by
Mitra Bio
See details and how to joinNCT07883954
1/2. fázisTaking people
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Where
Birmingham, Cardiff, Glasgow, Liverpool, London, Manchester, Newcastle upon Tyne, Southampton, Sutton
Életkor
18 év and over
People
1438 worldwide
Run by
BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00
2/3. fázisTaking people
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Where
Belfast, London, Southampton
Életkor
18 év and over
People
740 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00
3. fázisTaking people
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Where
Birmingham, Chelsea, Glasgow, London, Newcastle upon Tyne
Életkor
18 év to 70 év
People
670 worldwide
Run by
Iovance Biotherapeutics, Inc.
See details and how to joinNCT05727904 · EU 2022-503140-41-00
1/2. fázisTaking people
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Where
Birmingham, Leicester, London, Manchester, Southampton
Életkor
18 év and over
People
250 worldwide
Run by
BioInvent International AB
See details and how to joinNCT04752826 · EU 2023-509847-29-00
3. fázisNot yet taking people in Egyesült Királyság
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
Where
London
Életkor
18 év and over
People
550 worldwide
Run by
Scancell Ltd
See details and how to joinNCT07815574
1/2. fázisTaking people
Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC
Where
Manchester, Sutton
Életkor
18 év and over
People
62
Run by
Institute of Cancer Research, United Kingdom
See details and how to joinNCT07718243
2/3. fázisTaking people
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Where
Belfast, Birmingham, Bristol, Cambridge, Cardiff, Edinburgh, Glasgow, Leicester, Liverpool, London, Manchester, Metropolitan Borough of Wirral, Newcastle, Oxford, Sheffield, Southampton, Sutton
Életkor
1 év and over
People
30
Run by
Cancer Research UK
See details and how to joinNCT07440290
3. fázisTaking people
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Where
Liverpool, London, Manchester
Életkor
12 év and over
People
400 worldwide
Run by
Replimune, Inc.
See details and how to joinNCT06264180 · EU 2023-508612-29-00
1/2. fázisTaking people
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Where
London
Életkor
6 hónap to 17 év
People
370 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT02332668 · EU 2022-501257-36-00
3. fázisTaking people
Adjuvant Tebentafusp in High Risk Ocular Melanoma
Where
Liverpool, Northwood
Életkor
18 év and over
People
290 worldwide
Run by
European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT06246149 · EU 2023-510333-28-00
No phaseTaking people
The Multicentre Selective Lymphadenectomy Trial - 3
Where
London
Életkor
18 év and over
People
1500 worldwide
Run by
Melanoma Institute Australia
See details and how to joinNCT07049276
3. fázisTaking people
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Where
London, Metropolitan Borough of Wirral, Sheffield
Életkor
18 év and over
People
520 worldwide
Run by
IDEAYA Biosciences
See details and how to joinNCT07015190 · EU 2025-522387-32-00
3. fázisTaking people
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
Where
London, Manchester
Életkor
18 év and over
People
180 worldwide
Run by
ETOP IBCSG Partners Foundation
See details and how to joinNCT05522660
2/3. fázisTaking people
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Where
Liverpool, London
Életkor
18 év and over
People
280 worldwide
Run by
Replimune, Inc.
See details and how to joinNCT06581406 · EU 2023-508784-68-00
3. fázisTaking people
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Where
Birmingham, Cambridge, Leeds, London, Manchester, Middlesex, Sutton
Életkor
18 év and over
People
540 worldwide
Run by
Immunocore Ltd
See details and how to joinNCT05549297 · EU 2022-502732-39-00
3. fázisTaking people
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Where
Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Oxford, Surrey Quays
Életkor
18 év and over
People
680 worldwide
Run by
Immunocore Ltd
See details and how to joinNCT06112314
1/2. fázisTaking people
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
Where
Cambridge, Edinburgh, Glasgow, London, Manchester, Newcastle, Oxford, Preston
Életkor
18 év and over
People
135
Run by
NuCana plc
See details and how to joinNCT03829254
No phaseNot yet taking people in Egyesült Királyság
Investigation of the ROle of faT and inflAmmaTory Cells in mElanoma
Where
Manchester
People
20
Run by
The Christie NHS Foundation Trust
See details and how to joinNCT07293598
2/3. fázisTaking people
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Where
Belfast, Birmingham, Bristol, Cambridge, Cardiff, Edinburgh, Glasgow, Leicester, London, Manchester, Metropolitan Borough of Wirral, Newcastle, Oxford, Sheffield, Southampton
Életkor
18 év and over
People
30
Run by
Cancer Research UK
See details and how to joinNCT05768178
2/3. fázisTaking people
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
Where
Belfast, Birmingham, Bristol, Cambridge, Cardiff, Edinburgh, Glasgow, Leicester, Liverpool, London, Manchester, Metropolitan Borough of Wirral, Newcastle, Oxford, Sheffield, Southampton, Sutton
People
30
Run by
Cancer Research UK
See details and how to joinNCT05770102
2/3. fázisTaking people
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
Where
Belfast, Birmingham, Bristol, Cambridge, Cardiff, Edinburgh, Glasgow, Leicester, Liverpool, London, Manchester, Metropolitan Borough of Wirral, Newcastle, Oxford, Sheffield, Southampton, Sutton
People
30
Run by
Cancer Research UK
See details and how to joinNCT05770544